22 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250422821349/en/Compass-Pathways-Announces-Dosing-Complete-for-All-Participants-in-Part-A-of-Phase-3-COMP005-Trial-of-COMP360-Psilocybin-for-Treatment-Resistant-Depression
18 Apr 2025
// PRESS RELEASE
https://www.mikart.com/navigating-emerging-therapeutics-how-mikart-supports-cannabinoid-and-psilocybin-drug-development/
09 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionic-bloom-presents-cannadelic-miami-2025-announces-featured-speake-1012524
08 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionic-bloom-presents-cannadelic-miami-2025-1012505
28 Mar 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionic-bloom-to-host-live-5-meo-dmt-integration-session-1003212
26 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250326830443/en/Compass-Pathways-Announces-Completion-of-Recruitment-for-the-Phase-3-COMP005-Trial-of-COMP360-Psilocybin-for-Treatment-Resistant-Depression